NCT/Study#
NCT04623541 /
GCT3013-03
A Phase 1b/2, Open-Label, Safety And Efficacy Study Of Epcoritamab (GEN3013; Duobody®-CD3 X CD20) In Relapsed/Refractory Chronic Lymphocytic Leukemia
DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
